Compare FCNCP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCNCP | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 18141 | 34 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | FCNCP | SCLXW |
|---|---|---|
| Price | $20.35 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.8K | 4.6K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $19.97 | $0.04 |
| 52 Week High | $22.86 | $0.64 |
| Indicator | FCNCP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 45.65 |
| Support Level | $20.03 | $0.11 |
| Resistance Level | $20.68 | $0.18 |
| Average True Range (ATR) | 0.24 | 0.02 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 9.18 | 22.22 |
First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.